Dataset Information

Plasma Proteome adaptations in Feminising Gender Affirming Hormone therapy and Pregnancy

ABSTRACT: The dataset consists of longitudinal plasma proteomic data was generated using the Olink proteomics platform in plasma from transgender individuals receiving feminizing gender-affirming hormone therapy (GAHT). There were two treatment arms in the clinical trial that received different anti-androgens to inhibit testosterone. This included a cyproterone acetate ("CPA") group (n=20) and a spironolactone ("SPIRO") group (n=20). Proteomics was measured in plasma at baseline and 6 months following feminizing GAHT. Additionally data in a cross-sectional pregnancy cohort at first and third trimester, as well as a cis female and cis male control were generated.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Blood Plasma

SUBMITTER: Boris Novakovic

LAB HEAD: Boris Novakovic

PROVIDER: PAD000016 | Pride | 2025-09-17

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	Analysis_Report.pdf	Pdf
	GAHT_pregnancy_metadata_SDRF.tsv	Tabular
	Olink_CPA_SPIRO_GAHT_and_pregnancy.npx.csv	Csv
	X201SC23110522-Z01-F004_NPX.parquet	Other
	X201SC25020748-Z01-F001.parquet	Other

Items per page:

1 - 5 of 6

Publications

Plasma proteome adaptations during feminizing gender-affirming hormone therapy.

Nguyen Nhi N L NNL Celestra Den D Angus Lachlan M LM Mansell Toby T Shepherd Rebecca R Kim Bo Won BW Arman Bridget B Cabau Georgiana G Crișan Tania O TO Joosten Leo A B LAB Laberthonnière Camille C Burgner David D Tachedjian Gilda G Mhlanga Musa M Davey Rachel A RA Pang Ken C KC Cheung Ada S AS Saffery Richard R Novakovic Boris B

Nature medicine 20251020

Sex differences manifest in various traits, as well as in the risk of cardiovascular, metabolic and immunological conditions. Despite the clear physical changes induced by gender-affirming hormone therapy (GAHT), little is known about how it affects underlying physiological and biochemical processes. Here we examined plasma proteome changes over 6 months of feminizing GAHT in 40 transgender individuals treated with estradiol plus one of two antiandrogens: cyproterone acetate or spironolactone. T ...[more]

PMID: 41115957

Dataset Information

Plasma Proteome adaptations in Feminising Gender Affirming Hormone therapy and Pregnancy

Dataset's files

Publications

Plasma proteome adaptations during feminizing gender-affirming hormone therapy.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets

Similar Datasets

Evaluation of Olink Reveal Proximity Extension Assay for High-Throughput Proteomics: A Case Study Using NIST SRM 1950 and Spike-In Protein Standards
2025-06-03 | PAD000009 | Pride

TIMEPOINT, a phase 1 study of MTL-CEBPA in combination with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumours.
2025-05-07 | PXD060726 | Pride

Proteomic Profiling of MIS-C Patients Reveals Heterogeneity R 1 elating to Interferon 2 Gamma Dysregulation and Vascular Endothelial Dysfunction
2021-11-25 | PXD029375 | Pride

Individual glycemic responses to carbohydrates vary and reflect underlying metabolic physiology (Olink)
2025-03-31 | PAD000001 | Pride

People with HIV have higher percentages of circulating CCR5+ CD8+ T cells and lower percentages of CCR5+ regulatory T cells
2022-08-12 | PXD031628 | Pride

In-depth plasma proteomics of patients with suspected lung cancer (lung adenocarcinoma and non-cancer controls) with Olink Explore 3072
2025-11-10 | PAD000006 | Pride

Cooking methods affect Advanced Glycation End products and lipid profiles: a randomized cross-over study in healthy subjects
2025-01-24 | PXD059624 | Pride

Human Plasma Discovery Proteomics
2025-11-06 | PAD000022 | Pride

Human Plasma Discovery Proteomics
2025-10-10 | PAD000019 | Pride

A Technical Evaluation of Plasma Proteomics Technologies
2025-05-12 | PAD000002 | Pride